NCT03855332View on ClinicalTrials.gov

Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

December 6, 2022

Study Completion Date

January 6, 2023

Conditions
Small Vessel Cerebrovascular Disease
Interventions
DRUG

Sildenafil

See above

DRUG

Cilostazol

See above

DRUG

Placebo

Overencapsulated placebo

Trial Locations (1)

OX39DU

University of Oxford, Oxford

All Listed Sponsors
collaborator

Wellcome Trust

OTHER

lead

University of Oxford

OTHER

NCT03855332 - Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial | Biotech Hunter | Biotech Hunter